Table 2.
Characteristics of the studies included in this meta-analysis.
| Author, year | Age (T/C) | Number (T/C) | Duration of disease (T/C) | Gender (F/M) | Intervention (T) | Intervention (C) | Course | Outcomes | Region |
|---|---|---|---|---|---|---|---|---|---|
| Zheng and Huang, 2005 | 46.84 ± 12.52/47.59 ± 11.98 | 32/30 | 11.25 ± 9.72 y/11.82 ± 8.13 y | 32/30 | YQP (8 pills, tid)+metformin/gliclazide | Metformin/gliclazide | NR | ①③ | Hefei, Anhui |
| Deng et al., 2006 | 50 ± 11.6/49.8 ± 12.1 | 60/30 | 3.68 ± 2.56 y/3.43 ± 2.12 y | 51/39 | YQP (6 g, qid)+acarbose (50 mg, tid) | Acarbose (50 mg, tid) | 12 w | ①②⑤⑥⑦ | Hangzhou, Zhejiang |
| Zhao et al., 2008 | 41.1 ± 10.4/42.3 ± 11.7 | 48/46 | 5.2 ± 3.3 y/4.9 ± 3.2 y | 53/41 | YQP (8 pills, tid)+metformin (0.25 g, tid) | Metformin (0.25 g, tid) | 8 w | ①②③⑥ | Changsha, Hunan |
| Li and Wu, 2012 | 51.5 ± 4/53.5 ± 5.5 | 50/50 | 4.8 ± 0.9 y/5.1 ± 1.2 y | 53/47 | YQP (6 g, qid)+metformin (0.5 g, bid) | Metformin (0.5 g, bid) | 6 w | ①②③⑥ | Weinan, Shanxi |
| Tian, 2013 | 49.1 ± 4.7/48.3 ± 5.4 | 30/30 | 7.1 ± 0.6 y/6.6 ± 1 y | 28/32 | YQP decoction + hypoglycemic drugs | Hypoglycemic drugs | 4 w | ①②⑦ | Zhengzhou, Henan |
| Zhu, 2015 | 52.3 ± 5.1/53.1 ± 3.4 | 37/32 | 9.5 ± 2.1 y/10.5 ± 1.5 y | 41/28 | YQP (6 g, qid)+acarbose (50 mg, tid) | Acarbose (50 mg, tid) | 4 w | ②④⑦ | Wulanchabu, Neimenggu |
| Wang, 2017 | 56.27 ± 6.6/57.31 ± 4.2 | 60/60 | 5.56 ± 2.35 y/5.45 ± 2.56 y | 66/54 | YQP (6 g, qid)+metformin enteric capsules (0.5 g, tid)+ insulin | Metformin enteric capsules (0.5 g, tid)+ insulin | 12 w | ①③⑤⑥⑦ | Tianjin |
| Jing et al., 2019 | 46.87 ± 7.14/46.95 ± 7.54 | 40/40 | NR | 55/25 | YQP (6 g, qid)+metformin/gliclazide/insulin | Metformin/gliclazide/insulin | 12 w | ①②④⑦ | Taiyuan, Shanxi |
| Xiao et al., 2021 | 68.9 ± 5.2/69.7 ± 5.5 | 49/49 | 5.9 ± 1.8 y/5.6 ± 1.6 y | 57/41 | YQP (6 g, qid)+saxagliptin (5 mg, qd) | Saxagliptin (5 mg, qd) | 12 w | ①②③④⑤⑥⑦ | Nanyang, Henan |
| Wan et al., 2021 | 49.59 ± 5.37/49.65 ± 6.29 | 49/49 | 5.14 ± 0.92 y/5.24 ± 0.84 y | 58/40 | YQP (6 g, qid)+dapagliflozin (10 mg, qd) | Dapagliflozin (10 mg, qd) | 12 w | ①②③⑤⑥⑦ | Zhengzhou, Henan |
T: treatment group; C: control group; YQP : Yuquan Pill; F: female; M: male; NR: not reported; Y: year; W: week; ①: fasting blood glucose; ②: two-hour postprandial glucose; ③: glycosylated hemoglobin; ④: total cholesterol; ⑤: c-reactive protein; ⑥: overall effective rate; ⑦: adverse effects.